Cystic Fibrosis: Cost of Illness and Considerations for the Economic Evaluation of Potential Therapies

PharmacoEconomics

Volumn 21, Issue 14, 2003, Pages 1001-1024

  Krauth, Christian ^a   Jalilvand, Noushin ^a   Welte, Tobias ^b   Busse, Reinhard ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^c TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BENZAMIL; CHLORIDE; CIPROFLOXACIN; COLISTIN; CORTICOSTEROID; DORNASE ALFA; MUCOLYTIC AGENT; PANCREAS ENZYME; SODIUM CHANNEL BLOCKING AGENT; SODIUM PHENYLBUTYRATE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST OF ILLNESS; CYSTIC FIBROSIS; DIET THERAPY; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HEALTH CARE COST; HOME CARE; HOSPITAL PATIENT; HUMAN; LUNG ASPERGILLOSIS; MEDICAL SERVICE; PATIENT SELECTION; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; COST OF ILLNESS; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; HEALTH CARE COSTS; HOME CARE SERVICES; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAVENOUS; QUALITY OF LIFE;

EID: 0141924565     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321140-00002     Document Type: Review

References (79)

1. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122: 1-9
2. Dodge JA, Morison S, Lewis PA, et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child 1997; 77: 493-6
3. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996; 143: 1007-17
4. Lewis PA, Morison S, Dodge JA, et al. Survival estimates for adults with cystic fibrosis born in the United Kingdom between 1947 and 1967. The UK Cystic Fibrosis Survey Management Committee. Thorax 1999; 54: 420-2
5. Stutts MJ, Canessa CM, Olsen JC. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995; 269: 847-50
6. Guggino WB. Cystic fibrosis: the salt controversy. Cell 1999; 96: 607-10
7. Smith JJ, Travis SM, Greenberg EP, et al. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 229-36
8. Matsui H, Grubb BR, Tarran R. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airway disease. Cell 1998; 95: 1005-15
9. Davis PB. The gender gap in cystic fibrosis survival. J Gend Specif Med 1999; 2: 47-51
10. Kollberg H. Increasing survival of Swedish patients with CF. Acta Univ Carol Med Praha 1990; 36: 213-4
11. Frederiksen B, Lanng S, Koch C, et al. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996; 21: 153-8
12. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000 [published erratum appears in Thorax 1992; 47: 139]. Thorax 1991; 46: 881-5
13. Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999; 45: 61-73
14. van der Schans C, Prasad A, Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database Syst Rev 2000; (2): CD001401
15. Rodgers HC, Knox AJ. Pharmacological treatment of the biochemical defect in cystic fibrosis airways. Eur Respir J 2001; 17: 1314-21
16. Ratjen F. Changes in strategies for optimal antibacterial therapy in cystic fibrosis. Int J Antimicrob Agents 2001; 17: 93-6
17. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-5
18. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749-67
19. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23-30
20. Frangolias DD, Mahenthiralingam E, Rae S, et al. Burkholderia cepacia in cystic fibrosis. Variable disease course. Am J Respir Crit Care Med 1999; 160: 1572-7
21. Talmaciu I, Varlotta L, Mortensen J, et al. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 2000; 30: 10-5
22. Wark PA, Gibson PG. Allergic bronchopulmonary aspergillosis: new concepts of pathogenesis and treatment. Respirology 2001; 6: 1-7
23. Cobos N, Danes I, Gartner S, et al. DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres. DNase National Study Group. Eur J Pediatr 2000; 159: 176-81
24. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326: 1187-91
25. De Meester J, Smits JM, Persijn GG, et al. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant 2001; 20: 518-24
26. Granton JT, Kesten S. The acute effects of nasal positive pressure ventilation in patients with advanced cystic fibrosis. Chest 1998; 113: 1013-8
27. Pauly MV. The economics of cystic fibrosis. In: Lloyd-Still JD, editor. Textbook of cystic fibrosis. Boston: John Wright PSG Inc., 1983: 465-76
28. Robson M, Abbott J, Webb K, et al. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992; 47: 684-9
29. US Congress Office of Technology Assessment. Cystic fibrosis and DNA tests: implications of carrier screening. Washington: US Government Printing Office, 1992
30. Wildhagen MF, Verheij JB, Verzijl JG, et al. Cost of care of patients with cystic fibrosis in the Netherlands in 1990-1 [published erratum appears in Thorax 1997; 52: 204]. Thorax 1996; 51: 298-301
31. Johnson JA, Connolly M, Jacobs P, et al. Cost of care for individuals with cystic fibrosis in Alberta: a regression approach to determining important cost drivers [working paper]. Edmonton (AB): Institute of Health Economics, 1996: 99-2
32. Ireys HT, Anderson GF, Shaffer TJ, et al. Expenditures for care of children with chronic illnesses enrolled in the Washington State Medicaid Program, fiscal year 1993. Pediatrics 1997; 100: 197-204
33. Johnson JA, Connolly MA, Jacobs P, et al. Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase. Pharmacotherapy 1999; 19: 1159-66
34. Lieu TA, Ray GT, Farmer G, et al. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999; 103: e72
35. Wildhagen MF, Verheij JB, Verzijl JG, et al. The nonhospital costs of care of patients with CF in the Netherlands: results of a questionnaire. Eur Respir J 1996; 9: 2215-9
36. Ginsberg G, Blau H, Kerem E, et al. Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population. Health Econ 1994; 3: 5-23
37. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996, 46
38. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for the economic evaluation of pharmaceuticals: Canada. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997
39. Bosso JA, Stephenson SE, Herbst JJ. Feasibility and cost savings of intravenous administration of amino-glycosides in out-patients with cystic fibrosis. Drug Intell Clin Pharm 1985; 19: 52-4
40. Donati MA, Guenette G, Auerbach H. Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease. J Pediatr 1987; 111: 28-33
41. Gilbert J, Robinson T, Littlewood JM. Home intravenous antibiotic treatment in cystic fibrosis. Arch Dis Child 1988; 63: 512-7
42. Kane RE, Jennison K, Wood C, et al. Cost savings and economic considerations using home intravenous antibiotic therapy for cystic fibrosis patients. Pediatr Pulmonol 1988; 4: 84-9
43. Strandvik B, Hjelte L, Malmborg AS, et al. Home intravenous antibiotic treatment of patients with cystic fibrosis. Acta Paediatr 1992, 4
44. Bakker W, Vinks AA, Mouton JW, et al. Continuous intravenous home treatment of airway infections using ceftazidime administration via portable pump in patients with cystic fibrosis; a multicenter study. Ned Tijdschr Geneeskd 1993; 137: 2486-91
45. van Aalderen WMC, Mannes GPM, van Bommel G, et al. Continuous home intravenous antibiotic treatment of respiratory infections in 11 cystic fibrosis patients in the north of the Netherlands [in Dutch]. Ned Tijdschr Geneeskd 1993; 137: 2482-6
46. Pond MN, Newport M, Joanes D, et al. Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis. Eur Respir J 1994; 7: 1640-4
47. Bramwell EC, Halpin DM, Duncan SF, et al. Home treatment of patients with cystic fibrosis using the 'Intermate': the first year's experience. J Adv Nurs 1995; 22: 1063-7
48. van Aalderen WMC, Mannes GPM, Bosma ES, et al. Home care in cystic fibrosis patients. Eur Respir J 1995; 8: 172-5
49. Bosworth DG, Nielson DW. Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis. Pediatr Pulmonol 1997; 24: 42-7
50. Wolter JM, Bowler SD, Nolan PJ, et al. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost: aspects. Eur Respir J 1997; 10: 896-900
51. Rucker RW, Harrison GM. Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics 1974; 54: 358-60
52. Winter RJD, George RJD, Deacock SJ, et al. Self administered home intravenous antibiotic therapy in bronchiectasis and adult cystic fibrosis. Lancet 1984; 1: 1338-9
53. David TJ. Potential practical and legal problems with home administration of intravenous antibiotics for children with cystic fibrosis. In: David TJ, editor. Cystic fibrosis in children. Practical and legal aspects of intravenous antibiotic administration in the home. Amsterdam: Excerpta Medica (Glaxo), 1986: 3-14
54. Kuzemko JA, Williams KJ, Bigley J. Home intravenous treatment of pulmonary infections in cystic fibrosis. In: David TJ, editor. Cystic fibrosis in children. Practical and legal aspects of intravenous antibiotic administration in the home. Amsterdam: Excerpta Medica (Glaxo), 1986: 29-37
55. Graf von der Schulenburg JM, Greiner W, Klettke U, et al. Economic aspects in treatment of cystic fibrosis with chronic pulmonary pseudomonas infection. Ambulatory intravenous therapy in comparison with inpatient treatment [in German]. Med Klin 1997; 92: 626-9
56. Krauth C, Busse R, Smaczny C, et al. Cost comparison of hospital and ambulatory i.v. therapy in adult cystic fibrosis patients: results of a controlled prospective study [in German]. Med Klin 1999; 94: 541-8
57. Johannesson M. Avoiding double-counting in pharmacoeconomic studies. Pharmacoeconomics 1997; 11 (5): 385-8
58. Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity costs measurement through quality of life?. A response to the recommendations of the Washington Panel. Health Econ 1997; 6: 253-9
59. Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ 1997; 6: 511-4
60. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276; 1253-8
61. Rich D. Physicians, pharmacists and home infusion antibiotic therapy. Am J Med 1994; 97: 3-8
62. David TJ. Intravenous antibiotics at home in children with cystic fibrosis. J R Soc Med 1989; 82: 130-1
63. Ellis JM. Let parents give the care: IV therapy at home in cystic fibrosis. Professional Nurse 1989; 4: 589-92
64. Sheldon P, Bender M. High-technology in home care. An overview of intravenous therapy. Nurs Clin North Am 1994; 3: 507-19
65. Stiver HG, Trosky SK, Cote DD, et al. Self-administration of intravenous antibiotics: an efficient, cost-effective home care program. CMAJ 1982; 127: 207-11
66. Hammond LJ, Caldwell S, Campbell PW. Cystic fibrosis, intravenous antibiotics, and home therapy. J Pediatr Health Care 1991; 5: 24-30
67. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. Drug Therapy 1996; 335: 179-88
68. Davies J, Trindade MT, Wallis C, et al. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 1997; 23: 243-8
69. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637-42
70. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of Dornase Alfa in patients with advanced cystic fibrosis. Chest 1996; 110: 889-95
71. Milla CE. Long term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis. Thorax 1998; 53: 1014-7
72. Ranasinaha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolized recombinant human DNase in adults with stable stage cystic fibrosis. Lancet 1993; 342: 199-202
73. Shah PL, Scott SF, Geddes DM, et al. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 1995; 89: 499-502
74. Wilmott RW, Amin RS, Colin AA, et al. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 1996; 153: 1914-7
75. Oster G, Huse DM, Lacey MJ, et al. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Ann Pharmacother 1995; 29: 459-64
76. Menzin J, Oster G, Davies L, et al. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. Int J Technol Assess Health Care 1996; 12: 52-61
77. Brown TER, Glennie JL, Carleton BC. A pharmacoeconomic evaluation of DNase use in cystic fibrosis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1996
78. Ledson MJ, Wahbi Z, Convery RP, et al. Targeting of dornase alpha therapy in adult cystic fibrosis. J R Soc Med 1991; 7: 360-4
79. Marra CA, Carleton BC, Basmadjian D, et al. Cost of rhDNase in cystic fibrosis. Ann Pharmacother 1995; 29: 1050-1